{"doi":"10.1101/2022.07.31.502235","title":"Antigenic characterization of the SARS-CoV-2 Omicron subvariant BA.2.75","abstract":"Abstract The SARS-CoV-2 Omicron subvariant BA.2.75 emerged recently and appears to be spreading rapidly. It has nine mutations in its spike compared to BA.2, raising concerns it may further evade vaccine-elicited and therapeutic antibodies. Here, we found BA.2.75 to be moderately more neutralization resistant to sera from vaccinated/boosted individuals than BA.2 (1.8-fold), similar to BA.2.12.1 (1.1-fold), but more neutralization sensitive than BA.4/5 (0.6-fold). Relative to BA.2, BA.2.75 showed heightened resistance to class 1 and class 3 monoclonal antibodies to the receptor-binding domain, while gaining sensitivity to class 2 antibodies. The resistance was largely conferred by the G446S and R460K mutations. Of note, BA.2.75 was slightly resistant (3.7-fold) to bebtelovimab, the only therapeutic antibody with potent activity against all Omicron subvariants. BA.2.75 also exhibited higher receptor binding affinity than other Omicron subvariants. BA.2.75 provides yet another example of the ongoing evolution of SARS-CoV-2 as it gains transmissibility while incrementally evading antibody neutralization.","journal":"bioRxiv (Cold Spring Harbor Laboratory)","year":2022,"id":296646,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":23,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9489,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2022-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":350800,"name":"Sho Iketani","orcid":"0000-0002-3733-9556","position":1,"is_corresponding":false},{"id":809170,"name":"Zhiteng Li","orcid":"0000-0001-8535-7268","position":2,"is_corresponding":false},{"id":482831,"name":"Yicheng Guo","orcid":"0000-0001-5357-660X","position":3,"is_corresponding":false},{"id":847939,"name":"Andre Yanchen Yeh","orcid":"0000-0002-5761-528X","position":4,"is_corresponding":false},{"id":260169,"name":"Michael Liu","orcid":"0000-0003-2724-8797","position":5,"is_corresponding":false},{"id":105621,"name":"Jian Yu","orcid":"0000-0001-8604-4538","position":6,"is_corresponding":false},{"id":105636,"name":"Zizhang Sheng","orcid":"0000-0002-3253-3309","position":7,"is_corresponding":false},{"id":105637,"name":"Yaoxing Huang","orcid":"0000-0001-6270-1644","position":8,"is_corresponding":false},{"id":983528,"name":"Lihong Liu","orcid":"0000-0002-9956-2665","position":9,"is_corresponding":false},{"id":104013,"name":"David D. Ho","orcid":"0000-0003-1627-149X","position":10,"is_corresponding":false},{"id":105623,"name":"Qian Wang","orcid":"0000-0001-9549-3140","position":0,"is_corresponding":true}],"reference_count":29,"raw_metadata":null,"created_at":"2026-07-19T00:31:16.555318Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}